Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pupil dilation Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Study of Stimulus Parameters in Flicker Electroretinogram (ERG)

NCT02466607
View directory record Official record
Conditions
Retinopathy
Interventions
RETeval color flicker ERG, RETeval dilated versus un-dilated flicker ERG, pupil dilation
Device · Other
Lead sponsor
LKC Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Wearing-Off Period of Pharmacological Dilation and Anisocoria

NCT05238233
View directory record Official record
Conditions
Anisocoria
Interventions
Tropicamide, 1% Pilocarpine, Proparacaine Hydrochloride, Tono pen AVIA, VG4 Gonio, Reichert phoropter
Drug · Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Pupillary Dilation

NCT05274321
View directory record Official record
Conditions
Dilation
Interventions
Nanodropper, Standard Eye Dropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03112005
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 23, 2026, 7:02 AM EDT
Terminated Not applicable Interventional

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

NCT03016156
View directory record Official record
Conditions
Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions
CRADLE, Red reflex testing
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 7 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03078231
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751
View directory record Official record
Conditions
Healthy
Interventions
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Withdrawn Not applicable Interventional

Comparison of Rectal Trumpet and Standard Care

NCT00307476
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Rusch Nasopharyngeal Airway
Device
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Newark, Delaware • Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Terminated Not applicable Interventional Results available

Optimal Method for Mydriasis in Cataract Surgery

NCT02909140
View directory record Official record
Conditions
Cataract
Interventions
Topical phenylephrine 2.5%, Topical cyclopentolate 1%, Intracameral Lidocaine 1%, Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

NCT04620213
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Newport Beach, California • San Diego, California • Longwood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

Assessment of EyeArt Performance With Retinal Imaging Devices

NCT04302012
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
22 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

Assessment of EyeArt Performance With Retinal Cameras

NCT04984200
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Retinal imaging, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
22 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection

NCT06343350
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes
Interventions
OPTDR01 software application
Device
Lead sponsor
Optain Health
Industry
Eligibility
22 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Chula Vista, California • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images

NCT06241664
View directory record Official record
Conditions
Diabetic Retinopathy, DR, Diabetic Mellitus
Interventions
AEYE-DS Software
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 23, 2026, 7:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pupillary Dilation Reflex in Healthy Volunteers

NCT07746167
View directory record Official record
Conditions
Healthy Participants
Interventions
No intervention (observational study)
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation

NCT01820117
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, Ophthalmology Examination
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 23, 2026, 7:02 AM EDT
Completed No phase listed Observational

Comparison of Two OCT Device RNFL and GCIPL Measurements in Mild, Moderate, and Severe Glaucoma

NCT07350304
View directory record Official record
Conditions
Glaucoma
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Enrolling by invitation Not applicable Interventional

Pupillary Dilation During Post-Auricular Vagal Nerve Stimulation

NCT05870527
View directory record Official record
Conditions
Hearing Loss
Interventions
Electrical stimulator
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT06366217
View directory record Official record
Conditions
Dilation, Pupil Reaction Absent
Interventions
MydCombi Device, MydCombi Drug
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 7:02 AM EDT
Terminated No phase listed Observational

Diagnosis of ON With or Without MS or NMOSD

NCT04131764
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression, Optic Neuritis
Interventions
Reflex (Brightlamp Inc., Purdue University)
Diagnostic Test
Lead sponsor
Jagannadha R Avasarala
Other
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 23, 2026, 7:02 AM EDT